1. Home
  2. CKPT vs FRAF Comparison

CKPT vs FRAF Comparison

Compare CKPT & FRAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CKPT
  • FRAF
  • Stock Information
  • Founded
  • CKPT 2014
  • FRAF 1906
  • Country
  • CKPT United States
  • FRAF United States
  • Employees
  • CKPT N/A
  • FRAF N/A
  • Industry
  • CKPT Biotechnology: Pharmaceutical Preparations
  • FRAF Major Banks
  • Sector
  • CKPT Health Care
  • FRAF Finance
  • Exchange
  • CKPT Nasdaq
  • FRAF Nasdaq
  • Market Cap
  • CKPT 151.9M
  • FRAF 140.1M
  • IPO Year
  • CKPT 2017
  • FRAF N/A
  • Fundamental
  • Price
  • CKPT $3.00
  • FRAF $33.10
  • Analyst Decision
  • CKPT Strong Buy
  • FRAF
  • Analyst Count
  • CKPT 2
  • FRAF 0
  • Target Price
  • CKPT $13.50
  • FRAF N/A
  • AVG Volume (30 Days)
  • CKPT 998.1K
  • FRAF 7.3K
  • Earning Date
  • CKPT 11-12-2024
  • FRAF 01-28-2025
  • Dividend Yield
  • CKPT N/A
  • FRAF 3.83%
  • EPS Growth
  • CKPT N/A
  • FRAF 1.58
  • EPS
  • CKPT N/A
  • FRAF 3.20
  • Revenue
  • CKPT $47,000.00
  • FRAF $71,523,000.00
  • Revenue This Year
  • CKPT N/A
  • FRAF N/A
  • Revenue Next Year
  • CKPT $172,016.02
  • FRAF N/A
  • P/E Ratio
  • CKPT N/A
  • FRAF $10.44
  • Revenue Growth
  • CKPT N/A
  • FRAF 8.15
  • 52 Week Low
  • CKPT $1.38
  • FRAF $25.11
  • 52 Week High
  • CKPT $4.50
  • FRAF $34.15
  • Technical
  • Relative Strength Index (RSI)
  • CKPT 38.29
  • FRAF 63.75
  • Support Level
  • CKPT $3.07
  • FRAF $28.01
  • Resistance Level
  • CKPT $3.42
  • FRAF $33.80
  • Average True Range (ATR)
  • CKPT 0.21
  • FRAF 0.92
  • MACD
  • CKPT -0.03
  • FRAF 0.58
  • Stochastic Oscillator
  • CKPT 4.94
  • FRAF 87.91

About CKPT Checkpoint Therapeutics Inc.

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

About FRAF Franklin Financial Services Corporation

Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.

Share on Social Networks: